ArticleInfection and drug resistance2026
Rapid Identification of Drug-Resistant Tuberculosis Using Nanopore Targeted Next-Generation Sequencing from Sputum and Culture Isolates: Accuracy and Limitations.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Drug-resistant tuberculosis (DR-TB) complicates treatment and requires diagnostic approaches capable of comprehensive resistance profiling of Methods: DNA was extracted from 88 clinical samples, comprising 30 uncultured sputum specimens (10 MTB-positive, 10 non-tuberculous mycobacteria, and 10 mycobacteria-negative controls) to evaluate species identification, and 58 MTB culture isolates. The culture isolates represented diverse phenotypic resistance profiles, including mono-drug resistant, multidrug-resistant, and pre-extensively drug-resistant strains. tNGS profiles were compared with pDST to evaluate diagnostic performance for drug-resistance profiling, including sensitivity, specificity, and test agreement. Results: Profiling success in sputum samples was dependent on mycobacterial load. Among MTB-positive sputum specimens, 6 (60%) produced results, including 2 complete resistance profiles and 4 partial profiles limited to species identification; the remaining specimens failed due to low mycobacterial load (smear-negative and high Ct values). All NTM samples were correctly identified, and all mycobacteria-negative controls tested negative. In contrast, 57 of 58 (98.3%) culture isolates yielded complete resistance profiles. Compared with pDST, sensitivity and specificity exceeded 90% for most drugs (except streptomycin, 85.7% sensitivity), with very strong agreement (κ > 0.8). Conclusion: The ONT custom TB-DR sequencing assay provides comprehensive resistance profiling with high concordance to pDST in samples yielding complete sequencing profiles and enables species and lineage identification with a shorter analytical turnaround time compared with phenotypic testing. Performance in sputum specimens was influenced by mycobacterial load. Further studies involving larger and more diverse cohorts are needed to validate clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.